143 related articles for article (PubMed ID: 21418626)
1. Proteomic patterns analysis with multivariate calculations as a promising tool for prompt differentiation of early stage lung tissue with cancer and unchanged tissue material.
Waloszczyk P; Janus T; Alchimowicz J; Grodzki T; Borowiak K
Diagn Pathol; 2011 Mar; 6():22. PubMed ID: 21418626
[TBL] [Abstract][Full Text] [Related]
2. MALDI-ToF mass spectrometry for the rapid diagnosis of cancerous lung nodules.
Brégeon F; Brioude G; De Dominicis F; Atieh T; D'Journo XB; Flaudrops C; Rolain JM; Raoult D; Thomas PA
PLoS One; 2014; 9(5):e97511. PubMed ID: 24830707
[TBL] [Abstract][Full Text] [Related]
3. Application of serum SELDI proteomic patterns in diagnosis of lung cancer.
Yang SY; Xiao XY; Zhang WG; Zhang LJ; Zhang W; Zhou B; Chen G; He DC
BMC Cancer; 2005 Jul; 5():83. PubMed ID: 16029516
[TBL] [Abstract][Full Text] [Related]
4. Improved classification of breast cancer peptide and protein profiles by combining two serum workup procedures.
Velstra B; van der Burgt YE; Mertens BJ; Mesker WE; Deelder AM; Tollenaar RA
J Cancer Res Clin Oncol; 2012 Dec; 138(12):1983-92. PubMed ID: 22763645
[TBL] [Abstract][Full Text] [Related]
5. Proteomic patterns of tumour subsets in non-small-cell lung cancer.
Yanagisawa K; Shyr Y; Xu BJ; Massion PP; Larsen PH; White BC; Roberts JR; Edgerton M; Gonzalez A; Nadaf S; Moore JH; Caprioli RM; Carbone DP
Lancet; 2003 Aug; 362(9382):433-9. PubMed ID: 12927430
[TBL] [Abstract][Full Text] [Related]
6. Chaperonin (HSP60) and annexin-2 are candidate biomarkers for non-small cell lung carcinoma.
Ağababaoğlu İ; Önen A; Demir AB; Aktaş S; Altun Z; Ersöz H; Şanl A; Özdemir N; Akkoçlu A
Medicine (Baltimore); 2017 Feb; 96(6):e5903. PubMed ID: 28178129
[TBL] [Abstract][Full Text] [Related]
7. Identification of a 17-protein signature in the serum of lung cancer patients.
Sreseli RT; Binder H; Kuhn M; Digel W; Veelken H; Sienel W; Passlick B; Schumacher M; Martens UM; Zimmermann S
Oncol Rep; 2010 Jul; 24(1):263-70. PubMed ID: 20514471
[TBL] [Abstract][Full Text] [Related]
8. MALDI profiling of human lung cancer subtypes.
Gámez-Pozo A; Sánchez-Navarro I; Nistal M; Calvo E; Madero R; Díaz E; Camafeita E; de Castro J; López JA; González-Barón M; Espinosa E; Fresno Vara JA
PLoS One; 2009 Nov; 4(11):e7731. PubMed ID: 19890392
[TBL] [Abstract][Full Text] [Related]
9. Lung cancer diagnosis from proteomic analysis of preinvasive lesions.
Rahman SM; Gonzalez AL; Li M; Seeley EH; Zimmerman LJ; Zhang XJ; Manier ML; Olson SJ; Shah RN; Miller AN; Putnam JB; Miller YE; Franklin WA; Blot WJ; Carbone DP; Shyr Y; Caprioli RM; Massion PP
Cancer Res; 2011 Apr; 71(8):3009-17. PubMed ID: 21487035
[TBL] [Abstract][Full Text] [Related]
10. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
Han KQ; Huang G; Gao CF; Wang XL; Ma B; Sun LQ; Wei ZJ
Am J Clin Oncol; 2008 Apr; 31(2):133-9. PubMed ID: 18391596
[TBL] [Abstract][Full Text] [Related]
11. Serum albumin-bound proteomic signature for early detection and staging of hepatocarcinoma: sample variability and data classification.
Camaggi CM; Zavatto E; Gramantieri L; Camaggi V; Strocchi E; Righini R; Merina L; Chieco P; Bolondi L
Clin Chem Lab Med; 2010 Sep; 48(9):1319-26. PubMed ID: 20509833
[TBL] [Abstract][Full Text] [Related]
12. Proteomic strategies for the characterization and the early detection of lung cancer.
Massion PP; Caprioli RM
J Thorac Oncol; 2006 Nov; 1(9):1027-39. PubMed ID: 17409991
[TBL] [Abstract][Full Text] [Related]
13. MALDI imaging combined with hierarchical clustering as a new tool for the interpretation of complex human cancers.
Deininger SO; Ebert MP; Fütterer A; Gerhard M; Röcken C
J Proteome Res; 2008 Dec; 7(12):5230-6. PubMed ID: 19367705
[TBL] [Abstract][Full Text] [Related]
14. SELDI-TOF-MS of saliva: methodology and pre-treatment effects.
Schipper R; Loof A; de Groot J; Harthoorn L; Dransfield E; van Heerde W
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Feb; 847(1):45-53. PubMed ID: 17070117
[TBL] [Abstract][Full Text] [Related]
15. MALDI/SELDI protein profiling of serum for the identification of cancer biomarkers.
Cazares LH; Diaz JI; Drake RR; Semmes OJ
Methods Mol Biol; 2008; 428():125-40. PubMed ID: 18287771
[TBL] [Abstract][Full Text] [Related]
16. Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform.
Ummanni R; Mundt F; Pospisil H; Venz S; Scharf C; Barett C; Fälth M; Köllermann J; Walther R; Schlomm T; Sauter G; Bokemeyer C; Sültmann H; Schuppert A; Brümmendorf TH; Balabanov S
PLoS One; 2011 Feb; 6(2):e16833. PubMed ID: 21347291
[TBL] [Abstract][Full Text] [Related]
17. Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samples.
Freed GL; Cazares LH; Fichandler CE; Fuller TW; Sawyer CA; Stack BC; Schraff S; Semmes OJ; Wadsworth JT; Drake RR
Laryngoscope; 2008 Jan; 118(1):61-8. PubMed ID: 18043497
[TBL] [Abstract][Full Text] [Related]
18. Urinary proteome analysis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry with magnetic beads for identifying the pathologic presentation of clinical early IgA nephropathy.
He Q; Shao L; Yu J; Ji S; Wang H; Mao Y; Chen J
J Biomed Nanotechnol; 2012 Feb; 8(1):133-9. PubMed ID: 22515101
[TBL] [Abstract][Full Text] [Related]
19. Detection of lung cancer using plasma protein profiling by matrix-assisted laser desorption/ionization mass spectrometry.
Shevchenko VE; Arnotskaya NE; Zaridze DG
Eur J Mass Spectrom (Chichester); 2010; 16(4):539-49. PubMed ID: 20625202
[TBL] [Abstract][Full Text] [Related]
20. Classification of Thyroid Tumors Based on Mass Spectrometry Imaging of Tissue Microarrays; a Single-Pixel Approach.
Kurczyk A; Gawin M; Chekan M; Wilk A; Łakomiec K; Mrukwa G; Frątczak K; Polanska J; Fujarewicz K; Pietrowska M; Widlak P
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
